Roche Holding Ltd · SIX:RO
Roche — UBS European Conference 2026
24 slides from Roche's conference presentation, Nov 10, 2026
Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Roche: Set for future growth
Roche: Set for future growth Alan Hippe | CFO Roche UBS European Conference London, 10 November 2026
Slide 4: Business update, Upcoming pipeline readouts, Outlook
Business update Upcoming pipeline readouts Outlook
Slide 5: Significant progress made since Pharma Day 2025
Significant progress made since Pharma Day 2025 Continued strong operational efficiency, supporting delivery of the next wave of innovation Strong financial performance1 Positive Ph III readouts Significant pipeline progress giredestrant HER2 TKI3 Adj. ER+/HER2- eBC HER2+ BC +7% YTD (9M) 26 sales gr
Slide 6: Pharma: Up to 20 NMEs with launch potential by 2030
Pharma: Up to 20 NMEs with launch potential by 2030 Two recent additions: Tam-Peli in SCLC and NSCLC, and VEGF x IL6 DutaFab in DME afimkibart 0.5-1bn peak sales 1-2bn peak sales enicepatide IBD, RA, MASH >3bn peak sales Obesity +/- T2D 2-3bn peak sales sefaxersen1 tifeglipron (CT-996) IgAN Obesity
Slide 7: Diagnostics: Key technology launches driving future growth
Diagnostics: Key technology launches driving future growth Strong launch momentum of AXELIOS sequencing solution with very positive customer feedback Key platform launches AXELIOS 1 Sequencing launch momentum Molecular Lab Core Lab Near Patient Care ~1/3 of the Year 1 order target (100 instruments)
Slide 8: Expected 2026 currency impact
Expected 2026 currency impact USD / CHF Assumed avg. YTD 2026 -13% -9% -6% -3% 0.90 Assuming the 30 September 2026 exchange rates remain 0.86 0.84 0.83 stable until the end of 2026. 0.78 0.79 2026 impact1 is expected to be (%p): 0.80 0.80 Q1 Q2 Q3 Q4 0.79 0.77 0.79 0.79 0.78 0.80 0.81 0.81 0.82 0.83
Slide 9: 2026 guidance confirmed
2026 guidance confirmed LOE impact of roughly CHF 1bn expected for 2026 Group sales growth1 Mid single digit sales growth Core EPS growth1 High single digit Core EPS growth Dividend outlook Further increase dividend in Swiss francs 1. At CER: Constant exchange rates (avg. full year 2025); LOE: Loss
Slide 10: Business update, Upcoming pipeline readouts, Outlook
Business update Upcoming pipeline readouts Outlook
Slide 11: 2027: Key newsflow outlook
2027: Key newsflow outlook* Compound Indication Milestone divarasib 2L KRAS G12C+ NSCLC US/EU approval Lunsumio + Polivy 2L+ DLBCL US approval Lunsumio 2L+ FL US/EU filing Hemlibra Autoinjector US/EU approval PiaSky aHUS US/EU approval fenebrutinib RMS US approval fenebrutinib PPMS US approval Regul
Slide 12: Itovebi: Defining new SoC in PIK3CAm HR+ BC
Oncology/Hematology Itovebi: Defining new SoC in PIK3CAm HR+ BC Exploring combinations with giredestrant and CDK inhibitors (CDK4/6i, CDK4/2i, CDK4i) PI3Kα inh. with dual MoA Ph III (INAVO120) OS results in 1L HR+/HER2- mBC2 Clinical development program Median, months inavolisib untreated, stage II—
Slide 13: 1L DLBCL: SKYGLO has potential for BIC efficacy and safety
Oncology/Hematology 1L DLBCL: SKYGLO has potential for BIC efficacy and safety Continuing to advance the standard of care in a curative setting SKYGLO builds on POLARIX regimen in 1L DLBCL Ph Ib: 100% ORR with differentiated safety profile1 1L DLBCL treatment evolution 90% SKYGLO % Columvi + R-CHOP
Slide 14: Zemocimig (NXT007): BIC potential in Hemophilia A
Oncology/Hematology Zemocimig (NXT007): BIC potential in Hemophilia A Potential to achieve true hemostatic normalization; Ph III data expected late 2027 Next-gen FIXa/FX bispecific Ph I/II combined analysis1 Zemocimig molecule design Hemostatic normalization achieved Proportion of participants with
Slide 15: Afimkibart spearheading our IBD entry, backed by next-gen MoAs
Immunology Afimkibart spearheading our IBD entry, backed by next-gen MoAs IBD overview Roche in IBD Global IBD market (CHF bn)1 Key unmet needs ▪ Afimkibart, the only TL1A offering the possibility of SC administration for induction & maintenance ▪ Exploring TL1A in multiple immunological diseases, i
Slide 16: Afimkibart in UC: AMETRINE-1&2 enrollment complete
Immunology Afimkibart in UC: AMETRINE-1&2 enrollment complete Potential for subcutaneous administration in induction and maintenance Ph IIb (TUSCANY-2) in UC1 Ph III AMETRINE-1,2 and new AMETRINE–SC study design in UC AMETRINE-1: With treat-through design Efficacy Efficacy assessment assessment Indu
Slide 17: Leveraging our multispecifics pipeline for success in IBD
Immunology Leveraging our multispecifics pipeline for success in IBD Establishing IBD portfolio with afimkibart, complemented by novel MoAs p40xTL1A inhibits two key targets central to IBD IBD pipeline pathology: IL-12/ IL-23 and TL1A p40xTL1A bispecific*1,2 Pre- Molecule Ph I Ph II Ph III Status cl
Slide 18: Nivegacetor: Gamma-secretase modulator in Alzheimer's
Neurology Nivegacetor: Gamma-secretase modulator (GSM) in Alzheimer’s GSM offers complementary approach to target amyloid beta; ideal for intervention at earliest stages GSM alters APP processing, inhibits Aβ aggregation Ph I nivegacetor in healthy volunteers1 ▪ GSMs selectively target processing of
Slide 19: Trontinemab with BID potential in Alzheimer's disease in early 2028
Neurology Trontinemab with BID potential in Alzheimer’s disease in early 2028 Alzheimer’s disease overview Roche in Alzheimer’s disease Global prevalence Key unmet needs ▪ Opportunity for trontinemab to differentiate on (Mn patients)1 efficacy and safety as next gen Aβ antibody ▪ New Elecsys pTau217
Slide 20: Business update, Upcoming pipeline readouts, Outlook
Business update Upcoming pipeline readouts Outlook
Slide 21: Group sales, Core OP and COP margin momentum past 5 years
Group sales, Core OP and COP margin momentum past 5 years Accelerating growth after successfully navigating AHR cliff and COVID-19 pandemic Sales growth CHF rep vs CER Core OP growth CHF rep vs CER COP margin growth CHF rep vs CER 2025: +7% 2025: +13% 2025: +1.9%p (CER) (CER) (CER) 2024: +7% 2024: +
Slide 22: A strong base to deliver long-lasting future growth
A strong base to deliver long-lasting future growth Year end 2025 pipeline successes provide a clear path for sustained and strong growth beyond 2030 Potential launches by YE 2027 illustrative divarasib in 2L NSCLC vamikibart in UME Enspryng in MOGAD & TED Business development ▪ BD to further accele
Slide 23: Updated 2025-30 consensus outlook
Updated 2025-30 consensus outlook* Long-term growth outlook improved; significant upside potential remains on the late-stage pipeline Biosimilar gap (25-30) Consensus sales growth (25-30) Potential upside CHF Vabysmo 1.6bn Itovebi 1.0bn Columvi 0.9bn Assets with low to no coverage in Polivy 0.9bn cu
Slide 24: Doing now what patients need next
Doing now what patients need next